EGFR and non-small cell lung carcinoma: Previous clinical studies have demonstrated that gefitinib is capable of significantly prolonging progression-free survival (PFS) and improving the quality of life in NSCLC patients carrying EGFR mutations, compared with standard chemotherapy (2–4).